Trial Profile

Phase III Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relugolix (Primary) ; Leuprorelin
Indications Dysmenorrhoea; Endometriosis; Pelvic pain
Focus Registrational; Therapeutic Use
Sponsors ASKA Pharmaceutical

Most Recent Events

16 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information: JapicCTI194722).
08 Dec 2021 Primary endpoint (Change of maximum Visual Analogue Scale (VAS) score for endometriosis associated pelvic pain) has been met, as per Results published in the Fertility and Sterility
08 Dec 2021 Results published in the Fertility and Sterility

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com